Published in Cancer Weekly, February 14th, 2006
The DSMB meets regularly every 6 months to review unblinded safety data from the two pivotal phase III clinical trials. GTx is evaluating the use of Acapodene in an 80 mg dose for the treatment of multiple side effects of androgen-deprivation therapy (ADT) in men with advanced prostate cancer, and of Acapodene 20 mg dose for the prevention of prostate cancer in high risk men.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.